Currently, several clinical trials examining the combination of recombinant human IL-15 or IL-15 agonists with nivolumab and/or ipilimumab are ongoing in multiple types of advanced or refractory cancers (NCT02523469, NCT03228667, NCT03520686, and NCT033886320). Here, IL15 is linked to cancer.